JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Catholic University of the Sacred Heart
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Catholic University of the Sacred Heart (11)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
HemaSphere
2023
-
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
International Journal of Antimicrobial Agents, Vol. 62, Núm. 4
-
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
eClinicalMedicine, Vol. 58
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
2022
-
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Frontiers in Oncology, Vol. 12
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Blood, Vol. 139, Núm. 10, pp. 1588-1592
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
-
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Journal of Hematology and Oncology, Vol. 15, Núm. 1
2021
-
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Leukemia, Vol. 35, Núm. 12, pp. 3444-3454